RICHMOND, Va.--(BUSINESS WIRE)--Dynamics within the Contract Research Services industry are rapidly changing, going beyond a simple emphasis on cost savings and capacity, to increasingly stress innovative science and experienced project management, said Paul D’Sylva, Ph.D., chief executive officer of Commonwealth Biotechnologies, Inc. (“CBI”) (Nasdaq:CBTE). Speaking at the 2nd Annual Global R&D Congress held May 29 – 30 in Washington DC, Dr. D’Sylva presented a process to help pharmaceutical companies select the optimal contract research organization to fit their specific needs.
